Peptides DB
Research-centric peptide and protocol reference hub
Study 15 of 19Goserelin literatureJournal of clinical oncology : official journal of the American Society of Clinical Oncology · RCT · Phase 22023

Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.

The combination of darolutamide and goserelin showed a higher objective response rate and longer progression-free survival compared to darolutamide alone in patients with androgen receptor-positive salivary gland carcinoma.

Read at Journal of clinical oncology : official journal of the American Society of Clinical OncologyAdd to compare

Where it sits

this study against the rest of the goserelin corpus
4
Preclinical
11
Observational
0
Open-label
3
Randomised · this one
1
Reviews

Summary and findings

This study measured the efficacy and safety of darolutamide, both as monotherapy and in combination with goserelin, in patients with androgen receptor-positive salivary gland carcinoma. The trial involved 57 patients, with darolutamide administered at 600 mg orally twice daily and goserelin at 3.6 mg subcutaneously once every 28 days. The combination therapy showed a higher objective response rate compared to monotherapy.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Confirmed ORR of 45.2% (90% CI, 29.7 to 61.3) in the combination cohort, n=33.n=57Phase 22023

Abstract

The authors’ words, as Journal of clinical oncology : official journal of the American Society of Clinical Oncology supplied them

<h4>Purpose</h4>Salivary gland carcinoma (SGC), particularly salivary duct carcinoma (SDC), is a rare and aggressive malignancy with no standard systemic treatment. Androgen receptor (AR) expression is frequently detected in SDC, which suggests inhibition of the AR pathway as a therapeutic strategy. We conducted a prospective phase II trial of the efficacy and safety of darolutamide, a second-generation AR signaling inhibitor, as monotherapy or in combination with goserelin, in patients with AR-positive unresectable locally advanced (LA) or recurrent/metastatic (R/M) SGC.<h4>Methods</h4>DISCOVARY was a multicenter, single-arm, phase II trial conducted in Japan. Patients with unresectable LA or R/M AR-positive SGC were enrolled into two sequential cohorts, a monotherapy cohort (darolutamide 600 mg orally twice daily) and a combination cohort (darolutamide plus goserelin 3.6 mg subcutaneously once every 28 days). The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), safety, and health-related quality of life.<h4>Results</h4>Fifty-seven patients were enrolled (monotherapy, n = 24; combination, n = 33). In the monotherapy cohort, the confirmed ORR was 8.3% (90% CI, 1.5 to 24.0) and the median PFS was 5.7 months. In the combination cohort, ORR was 45.2% (90% CI, 29.7 to 61.3) and the median PFS was 13.1 months. Twelve-month OS rates were 91.3% and 87.0%, respectively. Most adverse events were grade 1 or 2 in severity, with no treatment-related deaths. Quality of life was preserved. No clear association between AR expression level or Ki-67 index and treatment response was evident in exploratory analysis.<h4>Conclusion</h4>Darolutamide demonstrated antitumor activity in AR-positive SGC, with numerically more favorable outcomes with goserelin. Darolutamide plus goserelin may represent a chemotherapy-sparing option in this rare malignancy.

Background

The study addresses the lack of standard systemic treatment for salivary gland carcinoma, particularly salivary duct carcinoma, which is aggressive and often androgen receptor-positive. Prior knowledge indicates that androgen receptor expression is common in this type of cancer, suggesting that targeting this pathway could be beneficial. This trial is significant as it explores the efficacy of darolutamide, a second-generation androgen receptor inhibitor, alone and in combination with goserelin in this rare malignancy.

Methods

This was a multicenter, single-arm, phase II trial involving patients with unresectable locally advanced or recurrent/metastatic androgen receptor-positive salivary gland carcinoma. A total of 57 patients were enrolled, with 24 receiving darolutamide alone and 33 receiving darolutamide in combination with goserelin. The primary outcome measure was the objective response rate, while secondary outcomes included progression-free survival, overall survival, safety, and quality of life.

Results

The primary endpoint showed a confirmed objective response rate of 45.2% (90% CI, 29.7 to 61.3) in the combination cohort. The median progression-free survival was 13.1 months for the combination therapy and 5.7 months for monotherapy. Twelve-month overall survival rates were reported as 91.3% for monotherapy and 87.0% for combination therapy. Adverse events were predominantly grade 1 or 2, with no treatment-related deaths.

Interpretation

The findings suggest that the combination of darolutamide and goserelin may offer improved outcomes compared to darolutamide alone, particularly in terms of objective response rate and progression-free survival. However, the clinical significance of the observed effect sizes should be interpreted cautiously, given the small sample size and lack of a control group. The exploratory analysis did not find a clear association between androgen receptor expression levels or Ki-67 index and treatment response, which may limit the understanding of the treatment's mechanisms.

Key findings

  • Confirmed ORR of 8.3% (90% CI, 1.5 to 24.0) in the monotherapy cohort, n=24.
  • Confirmed ORR of 45.2% (90% CI, 29.7 to 61.3) in the combination cohort, n=33.
  • Median PFS of 5.7 months in the monotherapy cohort.
  • Median PFS of 13.1 months in the combination cohort.
  • Twelve-month OS rates of 91.3% for monotherapy and 87.0% for combination therapy.

Limitations

  • Single-arm trial with no control group.
  • Small sample size (n=57).
  • Short follow-up duration.
  • Exploratory analysis showed no clear association between AR expression and treatment response.

Elsewhere in the Goserelin corpus

AFovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.JAMA oncology · 2026 · n=417 · Median PFS not reached vs 20.2 months with placebo, HR 0.55, 95% CI 0.38-0.77, 1-sided P < .001.HumanBUnderstanding risk perception and risk-reducing decision-making for surgery among individuals with a genetic predisposition to epithelial ovarian cancer.Journal of genetic counseling · 2026 · n=63 · 63 surveys and 20 interviews completed.HumanBEfficacy and safety of goserelin vs. leuprolide in premenopausal breast cancer patients receiving adjuvant endocrine therapy: A retrospective cohort study.Medwave · 2023 · n=187 · 88.89% of leuprolide patients achieved substantial estrogen reduction vs 92.78% of goserelin patients, RD = -3.89%, 95% CI: -12.18% to 4.40%; p = 0.354.HumanCOverexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy.Neuron · 2009 · Not reported in abstract.AnimalBExceptional Response to Short-course 177 Lu-PSMA Radioligand Therapy in a Patient With Metastatic Hormone-sensitive Prostate Cancer.Clinical nuclear medicine · 2023 · n=1 · PSA reduced from 433.75 ng/mL to 0.15 ng/mL after treatment.HumanBImpact of Lifestyle Patterns on Breast Cancer Prognosis: Evidence from a UK Biobank Survival Studybiorxiv-preprint · 2026 · 3-year AUC = 0.72 for breast cancer survival prediction.Human